Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717.

Míreanna comhchosúla

• Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.
  de réir: Foxwell, B, et al.
  Foilsithe / Cruthaithe: (2003)
• P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor.
  de réir: Sumariwalla, P, et al.
  Foilsithe / Cruthaithe: (2004)
• Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells.
  de réir: Cope, A, et al.
  Foilsithe / Cruthaithe: (1993)
• Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.
  de réir: Foxwell, B, et al.
  Foilsithe / Cruthaithe: (2000)
• Antinociceptive and antitumor activity of novel synthetic mononuclear Ruthenium (II) compounds
  de réir: A Shyam Sunder, et al.
  Foilsithe / Cruthaithe: (2013-01-01)